FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Joan Maurel

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Jordi Codony-Servat; Pilar Escudero; Carlos Fernández-Martos; Rosa Gallego; Xabier Garcia-Albeniz; Eva Martinez-Balibrea; Anna Martínez-Cardús; Vicente Alonso; Carles Pericay; Joan Maurel
Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer.
Enrique Casado; Beatriz Castelo; Cristóbal Belda-Iniesta; Emilio Burgos; Javier de Castro; Jaime Feliu; Carlos Fernández-Martos; Victor Moreno Garcia; Miguel Ángel García-Cabezas; María Teresa Gómez Del Pulgar; César Gómez Raposo; Manuel González Barón; Juan Carlos Lacal; Rocío A B López; Miriam López-Gómez; Joan Maurel; Juan Moreno Rubio; Jose Javier Sánchez; María Sereno; Pilar Vázquez; Francisco Zambrana; Paloma Cejas
Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target.
Sandra Pérez-Torras; Anna Vidal-Pla; Rosa Miquel; Salvador Navarro; VANESSA ALMENDRO; Neus Carbó; Laureano Fernández-Cruz; Pere Gascón; Joan Maurel; Adela Mazo
Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Joan Maurel (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jordi Codony-Servat; Pilar Escudero; Carlos Fernández-Martos; Rosa Gallego; Xabier Garcia-Albeniz; Eva Martinez-Balibrea; Anna Martínez-Cardús; Vicente Alonso; Carles Pericay; Joan Maurel
Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer.
Medical oncology (Northwood, London, England) 2013;30(1):428.
2012: Enrique Casado; Beatriz Castelo; Cristóbal Belda-Iniesta; Emilio Burgos; Javier de Castro; Jaime Feliu; Carlos Fernández-Martos; Victor Moreno Garcia; Miguel Ángel García-Cabezas; María Teresa Gómez Del Pulgar; César Gómez Raposo; Manuel González Barón; Juan Carlos Lacal; Rocío A B López; Miriam López-Gómez; Joan Maurel; Juan Moreno Rubio; Jose Javier Sánchez; María Sereno; Pilar Vázquez; Francisco Zambrana; Paloma Cejas
Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic target.
International journal of radiation oncology, biology, physics 2012;84(5):1151-8.
2011: Sandra Pérez-Torras; Anna Vidal-Pla; Rosa Miquel; Salvador Navarro; VANESSA ALMENDRO; Neus Carbó; Laureano Fernández-Cruz; Pere Gascón; Joan Maurel; Adela Mazo
Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening.
Cellular oncology (Dordrecht) 2011;34(6):511-21.
2011: Ana Celia Adet Caldelari; Juan Ramón Ayuso; Josep Antoni Bombi; Antoni Castells; Laureano Fernández-Cruz; Glòria Fernández-Esparrach; Faust Feu; Angels Ginés; Joan Maurel; Rosa Miquel; Salvador Navarro
[Malignancy predictive factors in pancreatic intraductal papillary mucinous neoplasm].
Medicina clínica 2011;137(14):631-6.
2011: Xavier García-Del-Muro; Auxiliadora Gómez España; Nuria Laínez; Antonio López-Pousa; Javier Martín; Javier Martínez-Trufero; Joan Maurel; Andrés Meana; Carlos Pericay; Andres Poveda; Jordi Rubió; José M Buesa; Juan Antonio Carrasco; Antonio Casado; Josefina Cruz; Ricardo Cubedo; Raquel de Andrés; Ana De Juan; Joaquín Fra
Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(18):2528-33.
2011: Enrique Casado; Beatriz Castelo; Cristóbal Belda-Iniesta; Montserrat Blanco; Emilio Burgos; Javier de Castro; Jaime Feliu; Carlos Fernández-Martos; Victor Moreno García; Miguel Ángel García-Cabezas; Damián García-Olmo; Manuel González-Barón; Noemí Manceñido; Joan Maurel; Rosa Miquel; Jose Javier Sánchez; Benito Sánchez-Llamas; María Sereno; Paloma Cejas
A combined strategy of SAGE and quantitative PCR Provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(12):4145-54.
2011: Gemma Carrera; Xabier Garcia-Albeniz; Juan Ramón Ayuso; Jorge Aparicio; Antoni Castells; Jordi Codony-Servat; Jaime Feliu; David Fuster; Rosa Gallego; Mario Pagés; Ferran Torres; Joan Maurel
Design and endpoints of clinical and translational trials in advanced colorectal cancer. a proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD).
Reviews on recent clinical trials 2011;6(2):158-70.
2011: Xavier García del Muro; Javier Martín; Joan Maurel; José Antonio Narváez; Eduardo Ortiz; Jaume Pomés; Antonio López Pousa; Andres Poveda; Luis Pérez Romasanta; Oscar Tendero; Joan M Viñals; Silvia Bagué; Ricardo Cubedo; Enrique de Álava
[Soft tissue sarcomas: clinical practice guidelines].
Medicina clínica 2011;136(9):408.e1-8.
2011: Xabier Garcia-Albeniz; Carles Pericay; Virginia Alonso-Espinaco; Vicente Alonso; Pilar Escudero; Carlos Fernández-Martos; Rosa Gallego; Pere Gascón; Sergi Castellví-Bel; Joan Maurel
Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2011;32(2):417-24.
2011: Carlos Hörndler; Rosa Gallego; Xabier García-Albeniz; Virginia Alonso-Espinaco; Vicente Alonso; Pilar Escudero; Mireya Jimeno; Javier Ortego; Jordi Codony-Servat; Carlos Fernández-Martos; Ana Calatrava; Mercedes Marín-Aguilera; Jenifer Muñoz; Sergi Castellví-Bel; Antoni Castells; Michele Rubini; Pere Gascón; Joan Maurel
Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study.
Cancer biology & therapy 2011;11(2):177-83.
2010: Joan Trabal; Pere Leyes; Maria Forga; Joan Maurel
Potential usefulness of an EPA-enriched nutritional supplement on chemotherapy tolerability in cancer patients without overt malnutrition.
Nutrición hospitalaria : organo oficial de la Sociedad Española de Nutrición Parenteral y Enteral 2010;25(5):736-40.
2010: Joan Maurel; Ana Sofia Martins; Andrés Poveda; José Antonio López-Guerrero; Ricardo Cubedo; Antonio Casado; Javier Martínez-Trufero; Juan Ramón Ayuso; Antonio Lopez-Pousa; Xabier Garcia-Albeniz; Xavier Garcia del Muro; Enrique de Alava
Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.
Cancer 2010;116(15):3692-701.
2009: Alejandro Martínez-Fernandez; Xabier García-Albeniz; Estela Pineda; Laura Visa; Rosa Gallego; Jordi Codony-Servat; Josep Maria Augé; Raquel Longarón; Pere Gascón; Antonio Lacy; Antoni Castells; Joan Maurel
Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients.
Annals of surgical oncology 2009;16(5):1412-20.
2009: Joan Maurel; Antonio López-Pousa; Ramón de las Peñas; Joaquín Fra; Javier Martín; Josefina Cruz; Antonio Casado; Andrés Poveda; Javier Martínez-Trufero; Carmen Balañá; María Auxiliadora Gómez; Ricardo Cubedo; Oscar Gallego; Belen Rubio-Viqueira; Jordi Rubió; Raquel Andrés; Isabel Sevilla; Juan Jose de la Cruz; Xavier García Del Muro; José M Buesa
Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(11):1893-8.
2009: Rosa Gallego; Jordi Codony-Servat; Xabier García-Albéniz; Enric Carcereny; Raquel Longarón; Angeles Oliveras; Mónica Tosca; Josep Maria Augé; Pere Gascón; Joan Maurel
Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer.
Endocrine-related cancer 2009;16(1):311-7.
2009: Antonio Soriano-Izquierdo; Ana C Adet; Rosa Gallego; Rosa Miquel; Antoni Castells; Maria Pellisé; Cristina Nadal; Miguel Angel López-Boado; Josep M Piqué; Pere Gascón; Carlos Conill; Antoni Bombí; Laureano Fernández-Cruz; Joan Maurel; Salvador Navarro
[Prediction of prognosis of patients with pancreatic adenocarcinoma with curative intent resection by means of histologic grade and pathologic N stage].
Medicina clínica 2009;132(5):163-71.
2009: VANESSA ALMENDRO; Elisabet Ametller; Susana García-Recio; Olga Collazo; Ignasi Casas; Josep M Augé; Joan Maurel; Pedro Gascón
The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin.
PloS one 2009;4(3):e4728.
2008: Andrés Poveda; Vicenç Artigas; Antonio Casado; José Cervera; Xavier García del Muro; José Antonio López-Guerrero; Antonio López-Pousa; Joan Maurel; Luis Ortega; Rafael Ramos; Ignacio Romero; María José Safont; Javier Martín
[Clinical practice guidelines in gastrointestinal stromal tumours (GEIS): update 2008].
Cirugía española 2008;84 Suppl 1():1-21.
2008: Jordi Marruecos; Carlos Conill; I Valduvieco; M Vargas; J Berenguer; Joan Maurel
Occipital condyle syndrome secondary to bone metastases from rectal cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2008;10(1):58-60.
2007: Cristina Nadal; Joan Maurel; Pere Gascon
Is there a genetic signature for liver metastasis in colorectal cancer?
World journal of gastroenterology : WJG 2007;13(44):5832-44.
2007: Eduardo Díaz-Rubio; Josep Tabernero; Auxiliadora Gómez España; Bartomeu Massutí; Javier Sastre; Manuel Chaves; Albert Abad; Alfredo Carrato; Bernardo Queralt; Juan José Reina; Joan Maurel; Encarnación González-Flores; Jorge Aparicio; Fernando Rivera; Ferrán Losa; Enrique Aranda
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(27):4224-30.
2007: Joan Maurel; Cristina Nadal; Xabier Garcia-Albeniz; Rosa Gallego; Enric Carcereny; VANESSA ALMENDRO; Maribel Mármol; Elena Gallardo; Josep Maria Augé; Raquel Longarón; Alejandro Martinez-Fernandez; Rafael Molina; Antoni Castells; Pere Gascón
Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients.
International journal of cancer. Journal international du cancer 2007;121(5):1066-71.
2007: Carlos Conill; Xavier Tomás; Andrés Combalia-Aleu; Antonio Palacín; Isabel Planas; Joan Maurel
Pathological femur fracture secondary to radiation therapy for soft tissue sarcoma.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2007;9(8):537-9.
2007: Raquel Losa; Joaquín Fra; Antonio López-Pousa; Marta Sierra; A Goitia; Esther Uña; R Nadal; J García Del Muro; M Gión; Joan Maurel; Pilar Escudero; Emilio Esteban; José M Buesa
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
Cancer chemotherapy and pharmacology 2007;59(2):251-9.
2006: Joan Maurel; Marta Martin-Richard; Carlos Conill; Marcelo Sánchez; Lourdes Petriz; Angels Ginès; Rosa Miquel; Rosa Gallego; Rosana Cajal; Carmen Ayuso; Salvador Navarro; Maribel Marmol; Cristina Nadal; Josep Maria Augé; Laureano Fernández-Cruz; Pere Gascón
Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer.
International journal of radiation oncology, biology, physics 2006;66(5):1391-8.
2006: Antonio López-Pousa; Raquel Losa; Javier Martín; Joan Maurel; Joaquín Fra; Marta Sierra; Antonio Casado; Javier García del Muro; Andres Poveda; Carmen Balañá; Javier Martínez-Trufero; Emilio Esteban; José M Buesa
Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.
British journal of cancer 2006;94(12):1797-802.
2006: Enric Carcereny; Joan Maurel
Monoclonal antibodies against epidermal growth factor receptor in advanced colorectal carcinoma: clinical efficacy and markers of sensitivity.
Reviews on recent clinical trials 2006;1(2):113-8.
2006: Rosa Gallego; Nuria Sanchez; Joan Maurel
Chemotherapy for elderly patients with advanced colorectal carcinoma.
Expert review of anticancer therapy 2006;6(5):795-800.
2006: Francisco Rodríguez-Moranta; Joan Saló; Angels Arcusa; Jaume Boadas; Virgínia Piñol; Xavier Bessa; Eduard Batiste-Alentorn; Antonio M Lacy; Salvadora Delgado; Joan Maurel; Josep M Piqué; Antoni Castells
Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(3):386-93.
2006: Antonio López-Pousa; Javier Martín; J Montalar; Ramón de las Peñas; Javier García del Muro; J Cruz; Joan Maurel; Pilar Escudero; Antonio Casado; José M Buesa
Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS).
Sarcoma 2006;2006():26986.
2005: Xavier Garcia del Muro; Antonio Lopez-Pousa; Javier Martin; José M Buesa; Javier Martinez-Trufero; Antonio Casado; Andres Poveda; Josefina Cruz; Isabel Bover; Joan Maurel
A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.
Cancer 2005;104(8):1706-12.
2005: Javier Martín; Andrés Poveda; Antonio Llombart Bosch; Rafael Ramos; José Antonio López-Guerrero; Javier García del Muro; Joan Maurel; Silvia Calabuig; Antonio Gutierrez; José L González de Sande; Javier Martínez; Ana De Juan; Nuria Laínez; Ferrán Losa; Valentín Alija; Pilar Escudero; Antonio Casado; Paula García; Pilar García; Remei Blanco; José M Buesa
Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):6190-8.
2005: Cristina Nadal; Joan Maurel; Rosa Gallego; Antoni Castells; Raquel Longarón; Maribel Marmol; Sergi Sanz; Rafael Molina; Marta Martin-Richard; Pere Gascón
FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4770-4.
2005: Javier Sastre; Eugenio Marcuello; Bartomeu Masutti; Matilde Navarro; Silvia Gil; Antonio Antón; Albert Abad; Enrique Aranda; Joan Maurel; Manuel Valladares; Inmaculada Maestu; Alfredo Carrato; José María Vicent; Eduardo Díaz-Rubio
Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3545-51.
2005: Joan Maurel; Andrés Cervantes; Carlos Conill; Ramón Salazar; Marta Martin-Richard; Manuel Pera; Hermini Manzano; Isabel Chirivella; Rosa Gallego; Xavier Marfa
Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma.
International journal of radiation oncology, biology, physics 2005;62(1):91-6.
2005: Francisco Rodríguez-Moranta; Antoni Castells; Rosa Miquel; Virgínia Piñol; Joan Maurel; Josep Fuster; Antonio M Lacy; Josep M Piqué
Late-occurring liver metastases in colorectal cancer.
Digestive diseases and sciences 2005;50(2):345-7.
2004: Joan Maurel; José M Buesa; Antonio López-Pousa; Xavier García Del Muro; María Jesús Quintana; Javier Martín; Antonio Casado; Javier Martínez-Trufero; Ramón de las Peñas; Carmen Balañá
Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS).
Journal of surgical oncology 2004;88(1):44-9.
2004: A Soriano-Izquierdo; Antoni Castells; Maria Pellisé; C Ayuso; Juan Ramón Ayuso; Teresa M De Caralt; Glòria Fernández-Esparrach; M A Ginès; A García-Criado; M Martín; Joan Maurel; Rosa Miquel; J A Bombí; Pere Gascón; Albert Biete; Josep M Piqué; Laureano Fernández-Cruz; Salvador Navarro
[Hospital registry of pancreatic tumors. Experience of the Hospital Clínic in Barcelona (Spain)].
Gastroenterología y hepatología 2004;27(4):250-5.
2004: Joan Maurel; Joaquín Fra; Antonio López-Pousa; Xavier García del Muro; Carmen Balañá; Antonio Casado; Javier Martín; Javier Martínez-Trufero; Ramón de las Peñas; José M Buesa
Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Cancer 2004;100(7):1498-506.
2003: Angel Artal-Cortés; Javier Martínez-Trufero; Ana Herrero; Teresa Puértolas; Vicente Alonso; Mónica Corral; Concepción Ceballos; Joan Maurel; Antonio Antón
Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer.
Anti-cancer drugs 2003;14(2):111-8.
2002: Antonio Soriano; Antoni Castells; A M Lacy; C Ayuso; Juan Ramón Ayuso; Carlos Conill; S Delgado; Josep Fuster; Juan Carlos García-Valdecasas; Angels Ginès; M Martín; Joan Maurel; Rosa Miquel; Meritxell Mollà; Ramón Vilana; Sergi Castellví-Bel; J Ignasi Elizalde; Virgínia Piñol; Maria Pellisé; Albert Biete; Pere Gascón; Josep M Piqué
[Evaluation of the efficacy and efficiency of a multidisciplinary unit for the treatment of patients with colorectal cancer].
Gastroenterología y hepatología 2002;25(10):579-84.
2001: Joan Maurel; Mirian Zorrilla; T Puertolas; Antonio Antón; Ana Herrero; Angel Artal; Vicente Alonso; Javier Martinez-Trufero; M M Puertas
Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors.
Anti-cancer drugs 2001;12(9):713-7.
2001: Noemi Reguart; Joan Maurel; Pere Gascón
[Complementary and alternative treatment to surgery in liver metastases of colorectal cancer].
Gastroenterología y hepatología 2001;24(4):210-7.
1998: Albert Abad; Bartomeu Massuti; E Blanco; Alfredo Carrato; Joan Maurel; Andrés Cervantes; Enrique Aranda; Antonio Antón; José María Vicent; J Dorta; M L Garcia de Paredes; A Ariza
Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial.
American journal of clinical oncology 1998;21(2):151-4.